AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2016
Jul 6, 2016
31289_dirs_2016-07-05_8ef26233-c041-4288-bdb5-5bd54d98270a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-07-01
Reporting Person: KOZARICH JOHN W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-07-01 | Common Stock | S | 100.0 | $119.47 | Disposed | 42883 | Direct |
| 2016-07-01 | Common Stock | S | 800.0 | $121.54 | Disposed | 42083 | Direct |
| 2016-07-01 | Common Stock | S | 100.0 | $122.23 | Disposed | 41983 | Direct |
Footnotes
F1: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.09 to $122.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.